Phil McEwan - Search Results

Year	Number of Results
2004	3
2005	7
2006	5
2007	1
2008	1
2009	1
2010	2
2011	4
2012	9
2013	5
2014	8
2015	11
2016	8
2017	10
2018	7
2019	13
2020	21
2021	13
2022	10
2023	8
2024	2

1

Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.

Davis JA, Booth D, McEwan P, Solomon SD, McMurray JJV, de Boer RA, Comin-Colet J, Bachus E, Chen J. Davis JA, et al. Among authors: mcewan p. Eur J Heart Fail. 2024 Mar 20. doi: 10.1002/ejhf.3197. Online ahead of print. Eur J Heart Fail. 2024. PMID: 38509642

2

Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial.

McEwan P, Davis JA, Gabb PD, Wheeler DC, Rossing P, Chertow GM, Correa-Rotter R, Tamura K, Barone S, Garcia Sanchez JJ. McEwan P, et al. Clin Kidney J. 2024 Feb 9;17(2):sfae025. doi: 10.1093/ckj/sfae025. eCollection 2024 Feb. Clin Kidney J. 2024. PMID: 38389710 Free PMC article.

3

Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis.

McEwan P, Hafner M, Jha V, Correa-Rotter R, Chernin G, De Nicola L, Villanueva R, Wheeler DC, Barone S, Nolan S, Garcia Sanchez JJ. McEwan P, et al. J Med Econ. 2023 Jan-Dec;26(1):1407-1416. doi: 10.1080/13696998.2023.2264715. Epub 2023 Oct 31. J Med Econ. 2023. PMID: 37807895 Free article. Review.

4

The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial.

Booth D, Davis JA, McEwan P, Solomon SD, McMurray JJV, De Boer RA, Comin-Colet J, Bachus E, Chen J. Booth D, et al. Among authors: mcewan p. Eur J Heart Fail. 2023 Aug;25(8):1386-1395. doi: 10.1002/ejhf.2940. Epub 2023 Jul 11. Eur J Heart Fail. 2023. PMID: 37344985

5

Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence.

McEwan P, Foos V, Martin B, Chen J, Evans M. McEwan P, et al. Diabetes Obes Metab. 2023 Jul;25(7):1830-1838. doi: 10.1111/dom.15040. Epub 2023 Mar 29. Diabetes Obes Metab. 2023. PMID: 36864575

6

Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation.

McEwan P, Harrison C, Binnie R, Lewis RD, Cohen-Solal A, Lund LH, Ohlsson M, von Haehling S, Comin-Colet J, Pascual-Figal DA, Wächter S, Dorigotti F, de Arellano AR, Ponikowski P, Jankowska EA. McEwan P, et al. Eur J Heart Fail. 2023 Mar;25(3):389-398. doi: 10.1002/ejhf.2788. Epub 2023 Mar 7. Eur J Heart Fail. 2023. PMID: 36718652 Free article.

7

Cost-effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure.

Miller RJH, Chew DS, Qin L, Fine NM, Chen J, McMurray JJV, Howlett JG, McEwan P. Miller RJH, et al. Among authors: mcewan p. Eur J Heart Fail. 2023 Feb;25(2):238-247. doi: 10.1002/ejhf.2777. Eur J Heart Fail. 2023. PMID: 36644849 Free article.

8

Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study.

McEwan P, Ponikowski P, Shiri T, Rosano GMC, Coats AJS, Dorigotti F, Ramirez de Arellano A, Jankowska EA. McEwan P, et al. J Med Econ. 2023 Jan-Dec;26(1):51-60. doi: 10.1080/13696998.2022.2155375. J Med Econ. 2023. PMID: 36476095 Free article.

9

Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.

McEwan P, Darlington O, Miller R, McMurray JJV, Wheeler DC, Heerspink HJL, Briggs A, Bergenheim K, Garcia Sanchez JJ. McEwan P, et al. Clin J Am Soc Nephrol. 2022 Dec;17(12):1730-1741. doi: 10.2215/CJN.03790322. Epub 2022 Nov 2. Clin J Am Soc Nephrol. 2022. PMID: 36323444 Free PMC article.

10

Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.

McEwan P, Boyce R, Sanchez JJG, Sjöström CD, Stefansson B, Nolan S, Correa-Rotter R, Rossing P, Chertow GM, McMurray JJV, Wheeler DC, Heerspink HJL. McEwan P, et al. Nephrol Dial Transplant. 2023 May 4;38(5):1260-1270. doi: 10.1093/ndt/gfac280. Nephrol Dial Transplant. 2023. PMID: 36301617 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

130 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year